Read + Share
Morita Y, Nannya Y, Ichikawa M, Hanamoto H, et al. ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa
in lower-risk MDS: W-JHS MDS01 trial. Int J Hematol 2022;116:659-668.
PMID: 35821550
|
 |
|
Morita Y, Nannya Y, Ichikawa M, Hanamoto H, et al. ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa
in lower-risk MDS: W-JHS MDS01 trial. Int J Hematol 2022;116:659-668.
PMID: 35821550
|
|
|
|